oct 5, 2012 - > Health Economics analyses 1 Results: 1. Compared with endoscopy, cytosponge + treatment is cheaper per participant with higher mean gains of QALYs and lower incremental cost-effectiveness ratio per QALY 2. Compared with endoscopy (17%), cytosponge reduces more incidence (19%) of oesophageal adenocarcinoma. Conclusion: Cytosponge is cost effective and would reduce cancer-related mortality compared with no screening

Description:

Method: microsimulation modelling of a hypothetical cohort of 50-years old men in UK with histories of gastro-esophageal reflux symptoms.
Assumptions:
1. prevalence of BE = 8%
2. invitation acceptance is 23% for endoscopy and 45% for cytosponge

Funding Supported by a grant from Addenbrooke's Charitable Trust (RG59162), core funding from the Medical Research Council (L.S., T.B., and R.C.F.), the Cambridge Experimental Medicine Centre (R.C.F.); the Medical Research Council (program number U015232027, to T.B. and L.D.S.). GL is funded by a Post-Doctoral Research Fellowship award from the National Institute for Health Research. The study sponsor(s) had no role in the study design and data collection, analysis and interpretation, nor in the writing and the decision to submit the paper for publication.

Added to timeline:

Date: